Acura Pharmaceuticals Company Description
Acura Pharmaceuticals is working to make it harder to abuse otherwise good drugs. The company has developed a technology to add abuse-deterring agents to commonly abused pharmaceuticals. If a drug with these agents (what Acura calls Aversion Technology) is taken in excess, the ingredients cause unpleasant symptoms shortly after ingestion. If a tablet is crushed and inhaled other ingredients will cause nasal irritation; and if an abuser attempts to dissolve the powder, it will form a non-injectable gel. Lead product candidate Acurox combines Aversion Technology with the commonly abused opioid painkiller oxycodone HCl.
View the Comprehensive Company Description for Acura Pharmaceuticals
The Company Description provides a historical perspective of Acura Pharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Acura Pharmaceuticals's evolution in the marketplace.
